The research compound in Ozempic®
Ozempic® is a type 2 diabetes medicine from Novo Nordisk. Its active compound is Semaglutide — which is what this catalogue supplies, as a research material.
This is not Ozempic®, and NOVALYTE LABS has no affiliation with Novo Nordisk. We supply the compound Semaglutide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Ozempic® is a trademark of Novo Nordisk, referenced here only to identify the compound.
Ozempic is Novo Nordisk’s brand for injectable semaglutide in type 2 diabetes. The same compound is sold as Wegovy for weight management and as Rybelsus in tablet form.
Semaglutide is a GLP-1 receptor agonist whose structural modifications — a C18 di-acid chain and a spacer — give it a half-life of roughly seven days, the basis for once-weekly dosing.
This catalogue supplies semaglutide as a research material. It is not Ozempic and is not intended for human use.
Semaglutide in this catalogue
0.25mg × 4 pens
Other brands using Semaglutide
The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.